Description
| Description | Epimedokoreanin B (EKB), an isoprenylated flavonoid isolated from Korean Epimedium, exhibited anticancer activity in human non-small cell lung cancer (NSCLC) A549 and NCI-H292 cells.Epimedokoreanin B also possesses anti-inflammatory and antibacterial activities, and may have scavenging activity against DPPH radicals, inhibiting the proliferation of MCF-7 and HepG2 in a dose-dependent manner. Epimedokoreanin B also exhibits anti-inflammatory and antibacterial activity, with DPPH radical scavenging activity, and inhibits the proliferation of MCF-7 and HepG2 in a dose-dependent manner.Epimedokoreanin B significantly inhibits the formation of N (α)-(carboxymethyl)lysine (CML) and N (Ï)-(carboxymethyl)arginine (CMA), and prevents clinical complications of diabetes mellitus through the inhibition of advanced glycation end-products (AGEs). |
| In vitro |
Epimedokoreanin B (compound6) (3.13-25 μM; 48 h) showed significant inhibitory effects on the proliferation of lung cancer cells A549, Calu1, and H1299. Epimedokoreanin B is non-toxic to human bronchial epithelial cells BEAS-2B.[1] Epimedokoreanin B (5 μM; 24 h) inhibits CD163 expression and IL-10 production, a known M2 marker, indicating that Epimedokoreanin B inhibits M2 polarization in human monocyte-derived macrophages (HMDM). Epimedokoreanin B inhibits STAT3 activation in HMDMs.[4] Epimedokoreanin B treatment inhibits cell proliferation and migration accompanied by cytoplasmic vacuolation in A549 and NCI-H292 cells. Autophagosome accumulation accompanied by blockage of autophagic flux was observed in Epimedokoreanin B-treated cells, consistent with the occurrence of endoplasmic reticulum stress.[2] |
| Source |
| Molecular Weight |
422.47 |
| Formula | C25H26O6 |
| CAS No. | 161068-53-7 |
Storage
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
